Toxoplasma gondii infects over one third of the global human population. Cerebral
toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to
50% of mortality with proper treatment and 80% without it. The fatality mainly due to the
brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given,
adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the
dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a
clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains
unclear. Moreover, its safety in immunodeficiency cases is still debatable.